NEW YORK, Dec. 5-Centagenetix will work with Boston University and Boston Medical Center to study the DNA of centenarians in the hopes of understanding diseases of aging, the company said in a statement today.
Centagenetix, a new company devoted to studying the genetics of aging, is working on a project to collect DNA from people worldwide who have reached the age of 100. It already has relationships with the Okinawan Centenarian Study, the Abyad Medical Center in Lebanon, and the Associazione Longevita in Naples.
Under the agreement with Boston University, both parties will share access to their sets of samples. Centagenetix gets exclusive commercial rights to develop treatments or diagnostics emerging from this research. Boston University and Boston Medical Center may use the discoveries in their research and will get royalties on any Centagenetix sales.
Boston University and Boston Medical Center jointly host the New England Centenarian study, an effort to understand the slowed process of aging in very old people.
The three partners are currently involved in furthering studies on the role of a gene on chromosome 4 in longevity.
Centagenetix is based in Cambridge, Mass. Boston Medical Center is a private nonprofit medical center affiliated with Boston University.